Wells Fargo raises Veeva Systems stock price target on AI monetization potential

Wells Fargo has lifted its price target on Veeva Systems shares to $330, up from $320, while keeping an Overweight rating. The stock is presently trading at $275, which, according to InvestingPro data, appears to be undervalued based on Fair Value analysis, potentially offering upside alongside a 9% target. Analysts now discuss Veeva's AI potential, focusing on how much value the company can capture through AI.

Two monetization paths from Falcon AI are being explored: a commission on ROI generated through cost savings from automated tasks, and ROI-based value capture from faster drug development timelines due to quicker reviews, submissions, and trial executions. Veeva's solid fundamentals, including a cash surplus over debt and a 75% gross profit margin, bolster this growth strategy.

The firm highlighted that only two top 20 pharmaceutical CRM decisions remain, with near-term debates revolving around execution and adoption. As Veeva CRM advances, Wells Fargo anticipates the focus shifting to the uptake of Vault CRM exclusives like Vault AI, Service Center, and Campaign Manager. Aspen CRM is viewed as a free long-dated call option on prospects outside of life sciences.

Veeva Systems recently reported robust second-quarter fiscal 2027 results, surpassing expectations with $928 million in revenue, exceeding estimates from Truist Securities and the consensus. This performance warranted price target increases from Truist Securities and TD Cowen, among others.